Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

(PEPN2111) A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

Principal Investigator: Twist, Clare J

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) …

Principal Investigator: Gopalakrishnan, Dharmesh

A Phase II Study of Type-1 Polarized Dendritic Cell (αDC1) -based Treatment in
Combination with Tumor-Selective Chemokine Modulation (CKM: Interferon alpha-2b,
Rintatolimod and Celecoxib) in Melanoma Patients with Primary PD-1/PD-L1 Resistance

Principal Investigator: Puzanov, Igor

A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery
versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

Principal Investigator: Gupta, Ajay

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined with IFN alpha2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients with Metastatic Triple Negative Breast Cancer

Principal Investigator: Gandhi, Shipra

(EAY191-N4): A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers (ComboMATCH Treatment Trial)

Principal Investigator: Levine, Ellis G

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

Principal Investigator: Malek, Ehsan

Community-based physical activity across the cancer continuum

Principal Investigator: Ray, Andrew D

(EAY191-S3) Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMatch Treatment Trial)

Principal Investigator: Levine, Ellis G

A022004:RANDOMIZED TRIAL OF CONSOLIDATION TARGETED ADJUVANT THERAPY WITH ENCORAFENIB AND CETUXIMAB VERSUS USUAL CARE FOR PATIENTS WITH STAGE II/III BRAF V600E COLON CANCER

Principal Investigator: Krishnamurthy, Anuradha

Phase 1/1b Trial of Talazoparib and Gemtuzumab ozogamicin in Adult Patients with Relapsed and/or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

A Phase 1/2 Study of EPI-7386 in Combination with
Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Chatta, Gurkamal S

A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma

Principal Investigator: Gupta, Ajay

Endobronchial Ultrasound Transbronchial Needle guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/II Study

Principal Investigator: Ivanick, Nathaniel M

A Phase 1 dose-escalation and expansion study to assess safety and preliminary antitumor activity of Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after previous…

Principal Investigator: Jain, Prantesh

Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

Principal Investigator: Wang, Eunice S

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Principal Investigator: Green, Steven D

An Open-Label Phase 1A/1B Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPa-Fc-CD40L) in Combination With Azacitidine or with Azacitidine and Venetoclax for the Treatment of Subjects With Higher Risk Myelodysplastic Syndrome (MDS) or Acute…

Principal Investigator: Green, Steven D

Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial

Principal Investigator: Levine, Ellis G

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy…

Principal Investigator: Iyer, Renuka V

NRG-GY025: A RANDOMIZED PHASE II TRIAL OF NIVOLUMAB AND IPILIMUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN PATIENTS WITH DEFICIENT MISMATCH REPAIR SYSTEM RECURRENT ENDOMETRIAL CARCINOMA

Principal Investigator: Zsiros, Emese

(ACCL2031) A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Principal Investigator: Twist, Clare J

(MCC 21704) A Multi-Institution Study of TGFb; imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue…

Principal Investigator: Gupta, Ajay

A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma

Principal Investigator: Gupta, Ajay

Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with…

Principal Investigator: Wang, Eunice S